A platform for research: civil engineering, architecture and urbanism
A platform for research: civil engineering, architecture and urbanism
Inhibitors of Calcium Oxalate Crystallization for the Treatment of Oxalate Nephropathies
Calcium oxalate (CaOx) crystal‐induced nephropathies comprise a range of kidney disorders, for which there are no efficient pharmacological treatments. Although CaOx crystallization inhibitors have been suggested as a therapeutic modality already decades ago, limited progress has been made in the discovery of potent molecules with efficacy in animal disease models. Herein, an image‐based machine learning approach to systematically screen chemically modified myo‐inositol hexakisphosphate (IP6) analogues is utilized, which enables the identification of a highly active divalent inositol phosphate molecule. To date, this is the first molecule shown to completely inhibit the crystallization process in the nanomolar range, reduce crystal–cell interactions, thereby preventing CaOx‐induced transcriptomic changes, and decrease renal CaOx deposition and kidney injury in a mouse model of hyperoxaluria. In conclusion, IP6 analogues based on such a scaffold may represent a new treatment option for CaOx nephropathies.
Inhibitors of Calcium Oxalate Crystallization for the Treatment of Oxalate Nephropathies
Calcium oxalate (CaOx) crystal‐induced nephropathies comprise a range of kidney disorders, for which there are no efficient pharmacological treatments. Although CaOx crystallization inhibitors have been suggested as a therapeutic modality already decades ago, limited progress has been made in the discovery of potent molecules with efficacy in animal disease models. Herein, an image‐based machine learning approach to systematically screen chemically modified myo‐inositol hexakisphosphate (IP6) analogues is utilized, which enables the identification of a highly active divalent inositol phosphate molecule. To date, this is the first molecule shown to completely inhibit the crystallization process in the nanomolar range, reduce crystal–cell interactions, thereby preventing CaOx‐induced transcriptomic changes, and decrease renal CaOx deposition and kidney injury in a mouse model of hyperoxaluria. In conclusion, IP6 analogues based on such a scaffold may represent a new treatment option for CaOx nephropathies.
Inhibitors of Calcium Oxalate Crystallization for the Treatment of Oxalate Nephropathies
Kletzmayr, Anna (author) / Mulay, Shrikant R. (author) / Motrapu, Manga (author) / Luo, Zhi (author) / Anders, Hans‐Joachim (author) / Ivarsson, Mattias E. (author) / Leroux, Jean‐Christophe (author)
Advanced Science ; 7
2020-04-01
13 pages
Article (Journal)
Electronic Resource
English
Calcium oxalate crystals in calcium oxalate stone disease
| British Library Conference Proceedings | 1996
Effects of phosphatidylcholine on calcium oxalate crystallization
| British Library Conference Proceedings | 1996
Renal handling of oxalate in hyperoxaluric calcium oxalate stone formers
| British Library Conference Proceedings | 1996
Tartronic Acid as a Potential Inhibitor of Pathological Calcium Oxalate Crystallization
| Wiley | 2024